PHAR and PHARM Related Headlines
Go Back- Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
- Pharming Group reports preliminary 2025 revenues and announces Investor Day
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
- Pharming Group provides update on previously announced G&A expense reduction plan
- FDA grants priority review to Pharming's leniolisib for children with APDS
- Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
PHAR and PHARM Related Press Releases
Go Back- Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
- Pharming Group reports preliminary 2025 revenues and announces Investor Day
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
- Pharming Group provides update on previously announced G&A expense reduction plan
- Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
PHAR and PHARM Related SEC Filings
Go Back- Form 6-K Pharming Group N.V. For: Jun 04
- Form 6-K Pharming Group N.V. For: May 28
- Form 6-K Pharming Group N.V. For: May 22
- Form 6-K Pharming Group N.V. For: Mar 12
- Form 6-K Pharming Group N.V. For: Feb 03
- Form 6-K Pharming Group N.V. For: Feb 01
- Form 6-K Pharming Group N.V. For: Jan 08
- Form 6-K Pharming Group N.V. For: Nov 06
- Form 6-K Pharming Group N.V. For: Oct 20
- Form 6-K Pharming Group N.V. For: Oct 06
- Form 6-K Pharming Group N.V. For: Oct 01
- Form 6-K Pharming Group N.V. For: Sep 10
- Form 6-K Pharming Group N.V. For: Sep 02
- Form 6-K Pharming Group N.V. For: Jul 31
